A Post Marketing Surveillance on Piqray in Korea

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

NCT03056755 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

NCT03671330 ·Status: COMPLETED ·Phase: PHASE2

Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib

NCT01070706 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

NCT07207070 ·Status: RECRUITING ·Phase: PHASE3

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

NCT04892693 ·Status: RECRUITING ·Phase: PHASE2

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

NCT04544189 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

NCT05512780 ·Status: UNKNOWN ·Phase: PHASE2

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

NCT00600275 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer

NCT02058381 ·Status: COMPLETED ·Phase: PHASE1

Talazoparib Maintenance Therapy in Triple-negative Breast Cancer

NCT04755868 ·Status: UNKNOWN ·Phase: PHASE2

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

NCT02154776 ·Status: COMPLETED ·Phase: PHASE1

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

NCT02297438 ·Status: COMPLETED ·Phase: PHASE3

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

NCT03439046 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

NCT05578053 ·Status: RECRUITING

A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia

NCT04943497 ·Status: COMPLETED

Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

NCT06650748 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

NCT03575065 ·Status: COMPLETED ·Phase: PHASE2

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

NCT04762979 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

NCT03437083 ·Status: COMPLETED

A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

NCT01684215 ·Status: COMPLETED ·Phase: PHASE2

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

NCT04546009 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

NCT04251533 ·Status: TERMINATED ·Phase: PHASE3

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

NCT02333370 ·Status: COMPLETED ·Phase: PHASE1

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

NCT05038735 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

NCT01958021 ·Status: COMPLETED ·Phase: PHASE3